3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
7
Ovarian Neoplasms
5
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Metastatic Castration Resistant Prostate Cancer
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Interventions
Filgrastim
13
Carboplatin
10
Cyclophosphamide
9
pembrolizumab
8
Radiosurgery
8
Ifosfamide
8
Magnetic Resonance Spectroscopy
7
Etoposide
7
Biopsy
7
Specimen Handling
6
Doxorubicin
6
X-Rays
5
Phantoms, Imaging
5
Peripheral Blood Stem Cell Transplantation
5
Paclitaxel
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
Cisplatin
5
pazopanib
4
palbociclib
4
Thiotepa
4
Temozolomide
4
Radiotherapy
4
Nuclear Medicine Department, Hospital
4
Nivolumab
4
Mesna
4
Melphalan
4
Docetaxel
4
Busulfan
4
Blood Specimen Collection
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
rucaparib
×
Genitourinary
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts